Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

This phase 2 study evaluated whether substituting bortezomib for vincristine in frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy could improve efficacy in non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL), centrally conf...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Blood
मुख्य लेखकों: Offner, Fritz, Samoilova, Olga, Osmanov, Evgenii, Eom, Hyeon-Seok, Topp, Max S., Raposo, João, Pavlov, Viacheslav, Ricci, Deborah, Chaturvedi, Shalini, Zhu, Eugene, van de Velde, Helgi, Enny, Christopher, Rizo, Aleksandra, Ferhanoglu, Burhan
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: American Society of Hematology 2015
विषय:
Clinical Trials and Observations
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC4616024/
https://ncbi.nlm.nih.gov/pubmed/26232170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-03-632430
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन